249 related articles for article (PubMed ID: 30520145)
61. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).
Harris JE; Rashighi M; Nguyen N; Jabbari A; Ulerio G; Clynes R; Christiano AM; Mackay-Wiggan J
J Am Acad Dermatol; 2016 Feb; 74(2):370-1. PubMed ID: 26685721
[No Abstract] [Full Text] [Related]
62. Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata.
Sedano R; Jairath V
Inflamm Bowel Dis; 2021 Apr; 27(5):e65. PubMed ID: 33484124
[No Abstract] [Full Text] [Related]
63. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
[No Abstract] [Full Text] [Related]
64. Tofacitinib in paediatric dermatoses: a narrative review.
Agarwal I; Panda M; Das A
Clin Exp Dermatol; 2022 Jul; 47(7):1256-1264. PubMed ID: 35279865
[TBL] [Abstract][Full Text] [Related]
65. The emerging safety profile of JAK inhibitors in rheumatic disease.
Winthrop KL
Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
[TBL] [Abstract][Full Text] [Related]
66. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
67. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
68. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
69. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
70. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
Serdaroğlu S; Engin B; Çelik U; Erkan E; Aşkın Ö; Oba Ç; Kutlubay Z
Dermatol Ther; 2019 May; 32(3):e12844. PubMed ID: 30693634
[No Abstract] [Full Text] [Related]
71. [Systemic treatment of vitiligo : Balance and current developments].
Meurer M; Ceric-Dehdari P
Hautarzt; 2017 Nov; 68(11):876-884. PubMed ID: 29030646
[TBL] [Abstract][Full Text] [Related]
72. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.
Vandiver A; Girardi N; Alhariri J; Garza LA
Int J Dermatol; 2017 Aug; 56(8):833-835. PubMed ID: 28322434
[TBL] [Abstract][Full Text] [Related]
73. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Hsu L; Armstrong AW
J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
[TBL] [Abstract][Full Text] [Related]
74. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
75. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
76. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
77. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
78. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
79. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
80. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
